

FOR IMMEDIATE RELEASE

CONTACT: John Lehmann
440.801.1540
jlehmann@imarcresearch.com


Jim Tabaczynski
440.835.4525
jptgroup@sbcglobal.net

IMARC Research Names Assistant Director

CLEVELAND, Ohio — IMARC Research, a Strongsville-based contract research organization has named Stephani Hulec its Assistant Director of Clinical Monitoring Services.

Ms. Hulec came to IMARC four years ago as a Clinical Research Associate (CRA.) She was later named a Lead CRA and is now assuming management responsibilities as the Assistant Director of Clinical Monitoring Services. She will help manage a department of 17 individuals – more than half of the company’s workforce.

Ms. Hulec holds an M.S. in Biology from the University of North Carolina at Charlotte and a B.A. in Biology from Thiel College. She also spent several years in research at The Cleveland Clinic.



Stephani Hulec

“In trying to keep up with IMARC’s accelerated growth, we recognized the need for additional management overall and especially in Clinical Monitoring which is the largest department in the company by people and revenue,” said Brandy Chittester, Director of Clinical Monitoring Services. “Looking around, we felt that – because of her background and work history at IMARC – Stephani would be the ideal person to step into that position.”

A privately-held, 15-year old company located in Strongsville, Ohio, IMARC assists the clinical research community in the pursuit of FDA and worldwide approvals. Our effectiveness is built on preparing, educating, complementing and guiding site teams from Day 1 — to control the complex management of trials via cost-effective monitoring, auditing and training services — which results in the support, proof and assurance they seek to overcome chaos caused by complexity while achieving

compliance through consistency. Providing committed, competent and confident consultation is how IMARC sets the highest standards for site outcomes and study partnerships. Sites monitored from the start by IMARC have never received an FDA warning letter. More information is available at:

www.imarcresearch.com

– 30 –

– *more* –